文献速递细菌感染、耐药与抗菌药物

细菌性血流感染治疗进展

Advances in the therapy of bacterial bloodstream infections.
PubMed 文献 · Clin Microbiol Infect · 2019-11-14

本文总结近5年关于细菌性血流感染抗生素方案的证据,聚焦药物选择、联合方案和最佳给药方案,覆盖耐药革兰阴性菌及金黄色葡萄球菌、肠球菌等难治病原体,指出新药使用、联合治疗和剂量优化方面仍存文献空白。

要点

  • 聚焦MRSA、VRE、CRE、MDR铜绿假单胞菌和CRAB等难治菌的治疗选择
  • 联合方案和新药证据有限,需关注高MIC、高接种量及肾功能增强等情形下的剂量优化
  • 金黄色葡萄球菌和肠球菌所致血流感染死亡率仍高

核心结论

  • 细菌性血流感染的诊治进展改善了临床结局,但金黄色葡萄球菌和肠球菌相关死亡率仍高,耐药革兰阴性菌使治疗选择受限。

研究设计与样本

  • 综述,检索MEDLINE近5年英文文献,聚焦药物选择、联合方案和最佳给药方案。

主要发现

  • 新药使用、联合方案及特定情形下的剂量优化(如肾功能增强、肾脏替代治疗、高接种量血流感染源、高MIC细菌)存在文献空白。

临床怎么用

  • 临床应针对MRSA、VRE、CRE、MDR铜绿假单胞菌和CRAB等难治菌,结合药敏和患者肾功能状态优化给药方案。

局限性

  • 仅检索近5年英文文献,未报告系统评价方法学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in the diagnostic and therapeutic management of patients with bloodstream infections (BSIs) have been achieved in the last years, improving clinical outcome. However, mortality associated with some pathogens, such as Staphylococcus aureus and Enterococcus spp., is still high. In addition, the spread of antibiotic resistance, mainly among Gram-negative bacteria, reduces treatment options in some circumstances. Therefore, interest in new drugs, combination regimens and optimal dosing schedules is rising. OBJECTIVES: Our aim is to summarize the current evidence on available antibiotic regimens for patients with bacterial BSI, focusing on drug choice, combination regimens and optimal dosing schedules. We selected bacteria that are difficult to manage because of virulence factors (i.e. methicillin-susceptible S. aureus), tolerance to antibiotic activity (i.e. Enterococcus faecalis), and/or susceptibility patterns (i.e. methicillin-resistant S. aureus, vancomycin-resistant enterococci, carbapenem-resistant Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii). SOURCES: MEDLINE search with English language and publication in the last 5 years as limits. CONTENT AND IMPLICATIONS: The literature gaps on the use of new drugs, the uncertainties regarding the use of combination regimens, and the need to optimize dosing schedules in some circumstances (e.g. augmented renal clearance, renal replacement therapy, high inoculum BSI sources, and isolation of bacteria showing high MICs) have been revised.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Giannella M, Bartoletti M, Gatti M, et al. Advances in the therapy of bacterial bloodstream infections. Clin Microbiol Infect. 2019. PMID: 31733377. doi:10.1016/j.cmi.2019.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。